Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective

Spanish pharma company Grifols said that the phase 3 ITAC clinical trial assessing hyperimmune globulins as a treatment for patients hospitalized with Covid-19 has failed ... Read More